Tucker DL - Search Results

1

Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.

Tucker DL, Naylor G, Kruger A, Hamilton MS, Follows G, Rule SA. Tucker DL, et al. Br J Haematol. 2017 Jul;178(2):327-329. doi: 10.1111/bjh.14122. Epub 2016 May 16. Br J Haematol. 2017. PMID: 27197509 Free article. No abstract available.

2

Novel agents in mantle cell lymphoma.

Tucker D, Rule S. Tucker D, et al. Expert Rev Anticancer Ther. 2017 Jun;17(6):491-506. doi: 10.1080/14737140.2017.1328280. Epub 2017 May 17. Expert Rev Anticancer Ther. 2017. PMID: 28480764 Review.

3

The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma.

Tucker D, Morley N, MacLean P, Vandenberghe E, Booth S, Parisi L, Rule S. Tucker D, et al. Br J Haematol. 2021 Mar;192(6):1035-1038. doi: 10.1111/bjh.16739. Epub 2020 May 23. Br J Haematol. 2021. PMID: 32445482 Free article.

4

Ibrutinib for mantle cell lymphoma.

Tucker DL, Rule SA. Tucker DL, et al. Future Oncol. 2016 Feb;12(4):477-91. doi: 10.2217/fon.15.342. Epub 2016 Jan 13. Future Oncol. 2016. PMID: 26759179 Review.

5

Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib.

Tucker DL, Mihailescu L, Riordan R, Rule S. Tucker DL, et al. Br J Haematol. 2017 Jul;178(1):153-155. doi: 10.1111/bjh.14118. Epub 2016 May 12. Br J Haematol. 2017. PMID: 27172457 Free article. No abstract available.

6

Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.

McCulloch R, Visco C, Eyre TA, Frewin R, Phillips N, Tucker DL, Quaglia FM, McMillan A, Lambert J, Crosbie N, Rule S. McCulloch R, et al. Among authors: tucker dl. Br J Haematol. 2020 May;189(4):684-688. doi: 10.1111/bjh.16416. Epub 2020 Feb 3. Br J Haematol. 2020. PMID: 32011729 Free article.

7

A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.

Tucker DL, Rule SA. Tucker DL, et al. Ther Clin Risk Manag. 2015 Jun 23;11:979-90. doi: 10.2147/TCRM.S73559. eCollection 2015. Ther Clin Risk Manag. 2015. PMID: 26150724 Free PMC article. Review.

8

Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies.

Jurczak W, Rule S, Townsend W, Tucker D, Sarholz B, Scheele J, Dyroff M, Gribben JG, Długosz-Danecka M, Zinzani PL. Jurczak W, et al. Leuk Lymphoma. 2021 Oct;62(10):2392-2399. doi: 10.1080/10428194.2021.1913139. Epub 2021 Apr 24. Leuk Lymphoma. 2021. PMID: 33896333

9

Does transcutaneous electrical nerve stimulation (TENS) alleviate the pain experienced during bone marrow sampling in addition to standard techniques? A randomised, double-blinded, controlled trial.

Tucker DL, Rockett M, Hasan M, Poplar S, Rule SA. Tucker DL, et al. J Clin Pathol. 2015 Jun;68(6):479-83. doi: 10.1136/jclinpath-2015-202908. Epub 2015 Mar 10. J Clin Pathol. 2015. PMID: 25759407 Clinical Trial.

10

Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.

Rampotas A, Wilson MR, Lomas O, Denny N, Leary H, Ferguson G, McKay P, Ebsworth T, Miller J, Shah N, Martinez-Calle N, Bishton M, Everden A, Tucker D, El-Hassad E, Hennessy B, Doherty D, Prideaux S, Faryal R, Hayat A, Keohane C, Marr H, Gibb A, Pocock R, Lambert J, Lacey R, Elmusharaf N, Clifford R, Eyre TA. Rampotas A, et al. Br J Haematol. 2021 Jul;194(2):365-377. doi: 10.1111/bjh.17513. Epub 2021 May 7. Br J Haematol. 2021. PMID: 33959947

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters